O	0	5	Phase
O	6	8	II
O	9	15	double
O	15	16	-
O	16	21	blind
O	22	29	placebo
O	29	30	-
O	30	40	controlled
O	41	51	randomized
O	52	57	study
O	58	60	of
B-intervention	61	72	armodafinil
O	73	76	for
B-condition	77	82	brain
I-condition	83	92	radiation
I-condition	92	93	-
I-condition	93	100	induced
I-condition	101	108	fatigue
O	108	109	.

O	110	116	Common
O	117	122	acute
O	122	123	-
O	123	127	term
O	128	132	side
O	133	140	effects
O	141	143	of
O	144	149	brain
O	150	162	radiotherapy
O	163	164	(
O	164	166	RT
O	166	167	)
O	168	175	include
O	176	183	fatigue
O	183	184	,
O	185	195	drowsiness
O	195	196	,
O	197	206	decreased
O	207	215	physical
O	216	227	functioning
O	227	228	,
O	229	232	and
O	233	242	decreased
O	243	250	quality
O	251	253	of
O	254	258	life
O	259	260	(
O	260	263	QOL
O	263	264	)
O	264	265	.

O	266	268	We
O	269	281	hypothesized
O	282	286	that
O	287	298	armodafinil
O	299	300	(
O	300	301	a
O	302	313	wakefulness
O	313	314	-
O	314	323	promoting
O	324	328	drug
O	329	334	known
O	335	337	to
O	338	344	reduce
O	345	352	fatigue
O	353	356	and
O	357	365	increase
O	366	375	cognitive
O	376	384	function
O	385	387	in
O	388	394	breast
O	395	401	cancer
O	402	410	patients
O	411	420	receiving
O	421	433	chemotherapy
O	433	434	)
O	435	440	would
O	441	447	result
O	448	450	in
O	451	458	reduced
O	459	466	fatigue
O	467	470	and
O	471	481	sleepiness
O	482	485	for
O	486	494	patients
O	495	504	receiving
O	505	510	brain
O	511	513	RT
O	513	514	.

O	515	516	A
O	517	522	phase
O	523	525	II
O	525	526	,
O	527	532	multi
O	532	533	-
O	533	546	institutional
O	546	547	,
O	548	555	placebo
O	555	556	-
O	556	566	controlled
O	567	577	randomized
O	578	583	trial
O	584	592	assessed
O	593	604	feasibility
O	605	607	of
O	608	619	armodafinil
O	620	623	150
O	624	626	mg
O	626	627	/
O	627	630	day
O	631	633	in
B-eligibility	634	646	participants
I-eligibility	647	656	receiving
I-eligibility	657	662	brain
I-eligibility	663	665	RT
O	665	666	,
O	667	671	from
O	672	676	whom
O	677	679	we
O	680	688	obtained
O	689	698	estimates
O	699	701	of
O	702	713	variability
O	714	717	for
O	718	725	fatigue
O	725	726	,
O	727	737	sleepiness
O	737	738	,
O	739	742	QOL
O	742	743	,
O	744	753	cognitive
O	754	762	function
O	762	763	,
O	764	767	and
O	768	777	treatment
O	778	784	effect
O	784	785	.

O	786	790	From
O	791	800	September
O	801	803	20
O	803	804	,
O	805	809	2010
O	809	810	,
O	811	813	to
O	814	821	October
O	822	824	20
O	824	825	,
O	826	830	2012
O	830	831	,
B-total-participants	832	834	54
O	835	847	participants
O	848	856	enrolled
O	857	861	with
O	862	864	80
O	864	865	%
O	866	875	retention
O	876	879	and
O	880	882	94
O	882	883	%
O	884	888	self
O	888	889	-
O	889	897	reported
O	898	908	compliance
O	908	909	.

O	910	915	There
O	916	920	were
O	921	923	no
B-outcome	924	929	grade
I-outcome	930	931	4
I-outcome	931	932	-
I-outcome	932	933	5
I-outcome	934	944	toxicities
O	944	945	,
O	946	949	and
O	950	953	the
B-outcome	954	963	incidence
I-outcome	964	966	of
I-outcome	967	972	grade
I-outcome	973	974	2
I-outcome	974	975	-
I-outcome	975	976	3
I-outcome	977	987	toxicities
O	988	991	was
O	992	999	similar
O	1000	1007	between
O	1008	1017	treatment
O	1018	1022	arms
O	1022	1023	,
O	1024	1027	the
O	1028	1032	most
O	1033	1039	common
O	1040	1042	of
O	1043	1048	which
O	1049	1053	were
B-outcome	1054	1061	anxiety
O	1062	1065	and
B-outcome	1066	1072	nausea
O	1073	1074	(
O	1074	1076	15
O	1076	1077	%
O	1077	1078	)
O	1078	1079	,
B-outcome	1080	1089	headaches
O	1090	1091	(
O	1091	1093	19
O	1093	1094	%
O	1094	1095	)
O	1095	1096	,
O	1097	1100	and
B-outcome	1101	1109	insomnia
O	1110	1111	(
O	1111	1113	20
O	1113	1114	%
O	1114	1115	)
O	1115	1116	.

O	1117	1122	There
O	1123	1127	were
O	1128	1130	no
O	1131	1144	statistically
O	1145	1156	significant
O	1157	1168	differences
O	1169	1171	in
B-outcome	1172	1175	end
I-outcome	1175	1176	-
I-outcome	1176	1178	RT
I-outcome	1179	1181	or
I-outcome	1182	1183	4
I-outcome	1184	1188	week
I-outcome	1189	1193	post
I-outcome	1193	1194	-
I-outcome	1194	1196	RT
O	1197	1205	outcomes
O	1206	1213	between
O	1214	1225	armodafinil
O	1226	1229	and
O	1230	1237	placebo
O	1238	1240	in
O	1241	1244	any
O	1245	1253	outcomes
O	1254	1255	(
O	1255	1265	Functional
O	1266	1276	Assessment
O	1277	1279	of
O	1280	1287	Chronic
O	1288	1295	Illness
O	1296	1303	Therapy
O	1304	1305	[
O	1305	1310	FACIT
O	1310	1311	]
O	1311	1312	-
O	1312	1319	Fatigue
O	1319	1320	,
O	1321	1326	Brief
O	1327	1334	Fatigue
O	1335	1344	Inventory
O	1344	1345	,
O	1346	1353	Epworth
O	1354	1364	Sleepiness
O	1365	1370	Scale
O	1370	1371	,
O	1372	1376	FACT
O	1376	1377	-
O	1377	1382	Brain
O	1382	1383	,
O	1384	1387	and
O	1388	1393	FACIT
O	1393	1394	-
O	1394	1403	cognitive
O	1404	1412	function
O	1412	1413	)
O	1413	1414	.

O	1415	1422	However
O	1422	1423	,
O	1424	1426	in
O	1427	1439	participants
O	1440	1444	with
O	1445	1449	more
O	1450	1458	baseline
O	1459	1466	fatigue
O	1466	1467	,
O	1468	1473	those
O	1474	1481	treated
O	1482	1486	with
O	1487	1498	armodafinil
O	1499	1502	did
O	1503	1509	better
O	1510	1514	than
O	1515	1520	those
O	1521	1524	who
O	1525	1533	received
O	1534	1537	the
O	1538	1545	placebo
O	1546	1548	on
O	1549	1552	the
O	1553	1556	end
O	1556	1557	-
O	1557	1559	RT
O	1560	1571	assessments
O	1572	1575	for
O	1576	1583	several
O	1584	1592	outcomes
O	1592	1593	.

O	1594	1605	Armodafinil
O	1606	1609	150
O	1610	1612	mg
O	1612	1613	/
O	1613	1616	day
O	1617	1620	was
B-outcome	1621	1625	well
I-outcome	1626	1635	tolerated
O	1636	1638	in
O	1639	1646	primary
O	1647	1652	brain
O	1653	1658	tumor
O	1659	1667	patients
O	1668	1678	undergoing
O	1679	1681	RT
O	1682	1686	with
O	1687	1691	good
O	1692	1702	compliance
O	1702	1703	.

O	1704	1709	While
O	1710	1715	there
O	1716	1719	was
O	1720	1722	no
O	1723	1730	overall
O	1731	1742	significant
O	1743	1749	effect
O	1750	1752	on
B-outcome	1753	1760	fatigue
O	1760	1761	,
O	1762	1767	those
O	1768	1772	with
O	1773	1780	greater
O	1781	1789	baseline
O	1790	1797	fatigue
O	1798	1809	experienced
O	1810	1818	improved
O	1819	1822	QOL
O	1823	1826	and
O	1827	1834	reduced
O	1835	1842	fatigue
O	1843	1847	when
O	1848	1853	using
O	1854	1865	armodafinil
O	1865	1866	.

O	1867	1872	These
O	1873	1877	data
O	1878	1885	suggest
O	1886	1890	that
O	1891	1892	a
O	1893	1904	prospective
O	1904	1905	,
O	1906	1911	phase
O	1912	1915	III
O	1916	1926	randomized
O	1927	1932	trial
O	1933	1935	is
O	1936	1945	warranted
O	1946	1949	for
O	1950	1958	patients
O	1959	1963	with
O	1964	1971	greater
O	1972	1980	baseline
O	1981	1988	fatigue
O	1988	1989	.
